De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
AMRUTANJAN Overzicht aandelen
Amrutanjan Health Care Limited produceert, levert en verkoopt ayurvedische pijnbalsems en dameshygiëneproducten.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 0/6 |
| Prestaties in het verleden | 2/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 4/6 |
Amrutanjan Health Care Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹768.55 |
| 52 Week Hoogtepunt | ₹862.60 |
| 52 Week Laag | ₹563.90 |
| Bèta | 0.76 |
| 11 maand verandering | -4.94% |
| 3 maanden verandering | -2.19% |
| 1 Jaar Verandering | 24.92% |
| 33 jaar verandering | -7.12% |
| 5 jaar verandering | 120.34% |
| Verandering sinds IPO | 1,563.17% |
Recent nieuws en updates
Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 31
Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 17Recent updates
Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 31Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 17We Think You Should Be Aware Of Some Concerning Factors In Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings
May 31Pinning Down Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) P/E Is Difficult Right Now
May 03Amrutanjan Health Care (NSE:AMRUTANJAN) Has Affirmed Its Dividend Of ₹1.00
Feb 12Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹2.60
Sep 02Amrutanjan Health Care's (NSE:AMRUTANJAN) Dividend Will Be ₹2.60
Aug 19Amrutanjan Health Care (NSE:AMRUTANJAN) Is Due To Pay A Dividend Of ₹2.60
Aug 05Amrutanjan Health Care (NSE:AMRUTANJAN) Has Announced A Dividend Of ₹1.00
Feb 17Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹1.00
Nov 08Amrutanjan Health Care (NSE:AMRUTANJAN) Will Pay A Dividend Of ₹2.60
Aug 18Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Vies For A Place In Your Dividend Portfolio: Here's Why
Apr 30Should You Be Adding Amrutanjan Health Care (NSE:AMRUTANJAN) To Your Watchlist Today?
Apr 08Introducing Amrutanjan Health Care (NSE:AMRUTANJAN), The Stock That Zoomed 162% In The Last Five Years
Mar 11Trade Alert: The Non-Executive Independent Director Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN), Govindan Raghavan, Has Just Spent ₹72k Buying A Few More Shares
Feb 24Is It Smart To Buy Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Before It Goes Ex-Dividend?
Feb 14Is Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Latest Stock Performance A Reflection Of Its Financial Health?
Feb 12Is Amrutanjan Health Care Limited (NSE:AMRUTANJAN) A Smart Choice For Dividend Investors?
Jan 30
Is There More To The Story Than Amrutanjan Health Care's (NSE:AMRUTANJAN) Earnings Growth?
Jan 17Here's Why I Think Amrutanjan Health Care (NSE:AMRUTANJAN) Is An Interesting Stock
Jan 04What Type Of Shareholders Make Up Amrutanjan Health Care Limited's (NSE:AMRUTANJAN) Share Registry?
Dec 22How Much is Amrutanjan Health Care's (NSE:AMRUTANJAN) CEO Getting Paid?
Dec 09If You Had Bought Amrutanjan Health Care (NSE:AMRUTANJAN) Stock Five Years Ago, You Could Pocket A 106% Gain Today
Nov 26Here's What We Like About Amrutanjan Health Care's (NSE:AMRUTANJAN) Upcoming Dividend
Nov 14Why Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Should Be In Your Dividend Portfolio
Oct 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Amrutanjan Health Care Limited's NSE:AMRUTANJAN) Stock?
Oct 10I Ran A Stock Scan For Earnings Growth And Amrutanjan Health Care (NSE:AMRUTANJAN) Passed With Ease
Sep 22What Percentage Of Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares Do Insiders Own?
Sep 01With Amrutanjan Health Care Limited (NSE:AMRUTANJAN) It Looks Like You'll Get What You Pay For
Aug 11Have Insiders Been Selling Amrutanjan Health Care Limited (NSE:AMRUTANJAN) Shares?
Jul 29Rendement voor aandeelhouders
| AMRUTANJAN | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | -0.02% | -1.3% | -3.6% |
| 1Y | 24.9% | 59.4% | 40.0% |
Rendement versus industrie: AMRUTANJAN presteerde slechter dan de Indian Pharmaceuticals -sector, die het afgelopen jaar een rendement van 59.4 % opleverde.
Rendement versus markt: AMRUTANJAN presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van 44.6 % opleverde.
Prijsvolatiliteit
| AMRUTANJAN volatility | |
|---|---|
| AMRUTANJAN Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 3.9% |
Stabiele aandelenkoers: AMRUTANJAN heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 5% ) van AMRUTANJAN is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1893 | 634 | Sambhu Sivalenka | www.amrutanjan.com |
Amrutanjan Health Care Limited produceert, levert en verkoopt ayurvedische pijnbalsems en hygiëneproducten voor vrouwen. Het bedrijf is actief in de segmenten OTC-producten, dranken en overige. Het bedrijf levert pijnbestrijdingsproducten, waaronder pijnbalsems en roll-ons; en rugpijn roll-ons, stick-on patch, body pain gels en joint muscle sprays.
Amrutanjan Health Care Limited Samenvatting
| AMRUTANJAN fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹22.18b |
| Inkomsten(TTM) | ₹425.73m |
| Inkomsten(TTM) | ₹4.27b |
52.1x
Koers/Winstverhouding5.2x
P/S-verhoudingIs AMRUTANJAN overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| AMRUTANJAN resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹4.27b |
| Kosten van inkomsten | ₹2.15b |
| Brutowinst | ₹2.12b |
| Overige uitgaven | ₹1.69b |
| Inkomsten | ₹425.73m |
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 14.73 |
| Brutomarge | 49.61% |
| Nettowinstmarge | 9.97% |
| Schuld/Eigen Vermogen Verhouding | 0.6% |
Hoe presteerde AMRUTANJAN op de lange termijn?
Bekijk historische prestaties en vergelijking